Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

Stopped early · Phase 3

Conditions studied: Niemann-Pick Type C Disease

In brief

This study was amended from expanded access to a clinical trial. Information will be collected about long-term safety and effectiveness of adrabetadex shots in the spine every 2 weeks. Participants who were already taking adrabetadex will receive their stable dose. Participants who have not ever taken it will start by receiving 400 mg. Participants will receive treatment every 2 weeks until their doctor finds it does not help them anymore, they withdraw, or the study is stopped for any reason. Participants will not receive additional study treatment after their participation in this protocol.

Key facts

Study ID

NCT03643562

Run by

Mandos LLC

People needed

27

Starts

2018-06-18

Expected to finish

2021-11-02

Last updated by the study team

2024-01-17

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be included in the study, a participant must meet the following criteria:
• Is male or female and at least 4 years of age at time of screening.
• Has a confirmed diagnosis of NPC and exhibits neurologic symptoms.
• Has written informed consent/assent to participate.
• Has the ability to undergo LP and IT drug administration.
• If taking miglustat (Zavesca®), must have been on a stable dose for the past 6 weeks and be willing to remain on a stable dose for the duration of participation in the study, or discontinue miglustat use at least 6 weeks before entry into the study (Day 1).
• If has a history of seizures, the condition is adequately controlled as per protocol requirements.
• Agrees to discontinue any investigational treatments (other than adrabetadex) for at least 1 month before first dose on Day 1.
• If engaging in heterosexual sex, agrees to use a protocol-defined method of contraception throughout the study, and until 30 days after completing the study.
• Has a responsible adult who the investigator determines is able and willing to comply with study requirements and a parent/guardian who will accompany the participant to study visits.

You may not qualify if…

• Participants will be excluded from the study if they meet any of the following criteria:
• Weighs less than 15 kg.
• Has a history of hypersensitivity reactions to any product containing 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) or has a history of hypersensitivity reactions or allergy to anesthesia/sedation.
• Has received treatment with any investigational product (other than adrabetadex) within 1 month prior to Day 1 of treatment.
• Is pregnant or nursing.
• Has systemic infection or uncontrolled psychosis.
• Has known history of a bleeding disorder.
• Has used anticoagulants within 2 months of entry into the study.
• Per protocol, or in the opinion of the investigator:
• has laboratory values that would preclude participation
• has suspected infection of the central nervous system (CNS)
• has a spinal deformity that could impact performance of repeated LPs
• has a serious skin infection in the lumbar region or evidence of obstructive or normal pressure hydrocephalus
• is unable to comply with the study requirements
• has a medical condition that might increase the risk of participation

Where it is running

• University of Arkansas System — Little Rock, Arkansas, United States
• Loma Linda University Health System — Loma Linda, California, United States
• Children's Hospital Los Angeles — Los Angeles, California, United States
• Children's Hospital of Orange County — Orange, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• Children's National Hospital — Washington D.C., District of Columbia, United States
• Rare Disease Research, LLC — Atlanta, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Gillette Children's Specialty Healthcare — Saint Paul, Minnesota, United States
• Children's Specialty Center of Nevada — Las Vegas, Nevada, United States
• NYU Langone Medical Center — New York, New York, United States
• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States
• Oregon Health & Science University — Portland, Oregon, United States
• The Children's Hospital at TriStar Centennial — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Dell Children's Medical Center of Central Texas — Austin, Texas, United States
• Carilion Medical Center, Carilion Clinic — Roanoke, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.